shutterstock_1397823566 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

BioMarin’s valoctocogene roxaparvovec for haemophilia A draws division on likelihood of FDA approval

Results of the 130-participant, open-label, single-armed, Phase III GENEr8-1 trial (NCT03370913) are expected in 2020.